



# Biotech Daily

Tuesday October 1, 2019

*Daily news on ASX-listed biotechnology companies*

- \* SEPTEMBER BDI-40 UP 0.5%, ASX200 UP 1%, BIG CAPS DOWN 1.4%, NBI DOWN 3%  
- PARADIGM UP 80%, ANTISENSE 57%; PRO MEDICUS DOWN 25%, AMPLIA 20%
- \* TODAY: ASX, BIOTECH UP: ACTINOGEN UP 467%; KAZIA DOWN 5%
- \* ACTINOGEN: 'XANAMEM IMPROVES COGNITION IN HEALTHY VOLUNTEERS'
- \* MESOBLAST '\$75m' TRADING HALT
- \* BENITEC TO RAISE \$3.3m, WARRANTS
- \* INNATE DIRECTOR CHRIS COLLINS INSIDER TRADING CHARGES
- \* OPTHEA RECEIVES \$14.6m FEDERAL R&D TAX INCENTIVE
- \* PARADIGM: 'PPS INHIBITS NERVE GROWTH FACTOR PAIN MEDIATORS'
- \* TGA REFUSES SUDA ARTIMIST APPEAL
- \* PHYLOGICA, VISION JOIN LIONS EYE; APPOINTS PROF SUE FLETCHER
- \* NEUROSCIENTIFIC: 'EMTIN-B HITS RETINA, OPTIC NERVE IN RABBITS'
- \* VISIONEERING APPOINTS MENICON NATURALVUE EUROPE DISTRIBUTOR
- \* CELLMID GERMANY, CHINA ÉVOLIS DISTRIBUTION DEALS
- \* CRYOSITE 1.3m CHAIRMAN OPTIONS AGM
- \* PHARMAUST REQUESTS 'CAPITAL RAISING' TRADING HALT
- \* RESAPP 'REGULATORY APPROVAL' TRADING HALT
- \* RACE APPOINTS DIRECTOR DR DANIEL TILLET CSO
- \* BIOTRON APPOINTS PHASE II HIV TRIAL SCIENTIFIC ADVISORY BOARD
- \* PATRYS APPOINTS DR PAMELA KLEIN DIRECTOR
- \* CORRECTION: ONCOSIL

## MARKET REPORT

The Australian stock market was up 0.82 percent on Tuesday October 1, 2019, with the ASX200 up 54.5 points to 6,742.8 points. Twenty-three of the Biotech Daily Top 40 stocks were up, 11 fell, four traded unchanged and two were untraded. All three Big Caps were up.

Actinogen was the best, closing up 4.2 cents or 466.7 percent to 5.1 cents with 454.6 million shares traded. Alterity climbed 13.8 percent; Amplia was up 12.5 percent; Dimerix rose 10.5 percent; Immutep, Opthea and Starpharma were up more than six percent; Prescient and Pro Medicus rose more than five percent; Cyclopharm, Genetic Signatures, Imugene, LBT, Osprey and Patrys improved more than four percent; Polynovo and Proteomics were up more than three percent; Cochlear, CSL, Next Science, Orthocell, Paradigm and Pharmaxis rose more than two percent; Nanosonics and Resmed were up more than one percent; with Clinuvel up 0.4 percent.

Kazia led the falls, down three cents or 5.3 percent to 54 cents, with 97,774 shares traded. Compumedics Optiscan, Telix and Uscom fell four percent or more; Cynata shed 2.5 percent; Antisense, Ellex, Medical Developments and Neuren were down more than one percent; with Avita down 0.85 percent.

## [BIOTECH DAILY TOP 40 INDEX \(BDI-40\)](#)

The Biotech Daily Top 40 Index (BDI-40) consolidated its gains in September, up a further 0.5 percent compared to the ASX200 up 1.3 percent. The BDI-40 was up 65.8 percent for the 12 months to September 30, 2019, compared to the ASX200 up 7.7 percent.

Avita has joined - and Mesoblast rejoins - the BDI-20 Billion Dollar Club, which now boasts six companies worth more than \$1 billion, with Pro Medicus sliding from just under \$4 billion to just under \$3 billion.

In the US, the Nasdaq Biotechnology Index (NBI) fell a further 3.3 percent in September and 18.4 percent for the year.

The collective value of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) fell 1.4 percent to \$146,580 million in September, with Resmed leading the falls, down 11.4 percent to \$28,487 million, Cochlear retreating 2.4 percent to \$12,032 million and CSL slipping 0.6 percent to \$106,061 million.

Twenty-five of the BDI-40 stocks were up, with 14 up by more than 10 percent and seven up by more than 20 percent. Fourteen companies fell, with four down by more than 10 percent. At \$76 million, Imugene was unchanged for the month and the year.

Paradigm jumped 80.2 percent to \$555 million, followed by Antisense up 57.1 percent to \$33 million, Kazia (45.8%), Mesoblast (45.6%), Impedimed (33.8%), Avita (29.7%), Prescient (23.5%), Proteomics (18.2%), Telix (15.4%), Uscom (13.3%), Resonance (12.8%), Volpara (12.6%), Next Science (11.8%) and Actinogen (11.1%).

In August, Pro Medicus added \$654 million to the index, but in September retreated \$947 million or 24.7 percent to \$2,893 million. In previous years, the loss of \$1 billion from the index was dire – if not catastrophic.

Today, the gains by Avita, Mesoblast and Paradigm compensated for the loss. Amplia (formerly Innate) fell \$1 million or 20 percent to \$4 million, followed by Cyclopharm (15.1%), Compumedics (14.8%), Oncosil (8.9%), Patrys (8.0%), Universal Biosensors (7.9%), Ellex (7.1%) and Dimerix (6.25%).


Outside the BDI-40, Alcidion at \$228 million, Botanix at \$241 million and Painchek at \$277 million, were at their highest capitalizations since listing. Probiotec at \$111 million is at its highest since being added to the Biotech Daily lists. Probiotec chief financial officer Jared Stringer told Biotech Daily the company may have reached this level about 10 years ago.

Cannabis Corner slid a further 3.2 percent to \$1,562 million, with six of the 18 companies rising, 11 falling and one unchanged.


In the US Eyepoint (formerly Psivida) was up 19.8 percent to \$284 million, Queensland's Protagonist fell 8.1 percent to \$467 million and Redhill with Australian assets was down 7.2 percent to \$296 million.

Following a further capital raising, the Australian held value in Vaxart (formerly Aviragen and Biota) has been diluted to the point that we shall no longer cover the company – despite about 9,000 Australian investors retaining shares in the company.


**BDI-40 v ASX200 Jun 30, 2006 to Sep 30, 2019- Adjusted**



**Big Caps \$m (Cochlear, CSL, Resmed) Sep 30, 2016 – Sep 30, 2019**



**BDI-40 (\$m) v S&P ASX 200 – Sep 30, 2018 - Sep 30, 2019 (current, raw data)**



## ACTINOGEN MEDICAL

Actinogen leapt as much as 467 percent on news that its 42-patient Xanahes study shows “statistically significant ... cognitive improvement” in healthy, elderly subjects.

Actinogen said the placebo-controlled study investigated the safety of 20mg Xanamem, dosed in healthy elderly subjects daily for 12-weeks.

The company said the results showed “a good safety profile with no serious adverse events observed” and a “statistically significant reduction in serum cortisol following treatment with Xanamem 20mg daily” ( $p < 0.001$ ).

In May, the company said its 186-patient, phase II Xanadu trial of Xanamem for Alzheimer’s disease “did not achieve statistical significance”, and further study of the effects of higher doses of Xanamem on cortisol production in the brain would be undertaken (BD: May 7, 2019).

Today, Actinogen said there was a “significant improvement in cognition in trial participants dosed with Xanamem ... compared to placebo”.

Actinogen chief executive officer Dr Bill Ketelbey told Biotech Daily that 30 subjects had received Xanamem and 12 had been administered a placebo.

The company said that the “breakthrough results” reinforced the hypothesis that lowering persistently-raised cortisol levels in the brain could positively enhance cognition.

Actinogen said the trial used the Cogstate cognitive test battery which showed cognitive improvement in three of the six domains investigated after 12 weeks of treatment.

The company said the cognitive test measured cognitive improvement with a “quantitative measure” of effect size, with a result greater than 0.8 indicating a “large treatment effect” and greater than 0.5 representing a “medium treatment effect”.

Actinogen said that “these results demonstrate an encouraging clinical efficacy signal in cognitive domains that are core to cognitive evaluation across many diseases”.

The company said that the results at week-12 had recorded a measure of 0.83 in the “one back test” evaluating working memory which had increased from 0.64 at week-2, to 0.78 at week-4 and 0.64 at week-8 ( $p < 0.01$ ).

Actinogen said that in the visual attention identification test the average change was from 0.19 at week-2 to 0.67 at week-12 ( $p = 0.05$ ).

The company said that the psychomotor function detection test demonstrated a non-statistically significant change from 0.47 at week-2 to 0.76 at week-12 ( $p = 0.09$ ).

Actinogen said that the improved cognition in the Xanahes trial supported “Xanamem’s potential for the treatment of Alzheimer’s disease and other conditions associated with cognitive impairment, including mood disorders like bipolar disorder, and schizophrenia”.

Dr Ketelbey said that the data from Xanahes and the other ongoing studies provided a “much clearer picture of Xanamem’s pharmacology, potential efficacy, safety, and mechanism of action; all of which will aid substantially in planning the future clinical development and commercialization strategy for the drug”.

Xanahes trial lead investigator Prof Michael Woodward from Melbourne’s Austin Health said with many past failures in the development of Alzheimer’s drugs, the Xanahes results “renewed hope for a treatment breakthrough for this devastating disease”.

The company said that cognition enhancement in the Xanahes trial “supports Xanamem’s potential for the treatment of Alzheimer’s disease and other conditions associated with cognitive impairment, including mood disorders like bipolar disorder, and schizophrenia”.

Dr Ketelbey said that “these are the results we have been looking for”.

“They are hugely important for the development of Xanamem and for the potential for Xanamem to treat Alzheimer’s disease and other conditions associated with cognitive impairment,” Dr Ketelbey said.

Actinogen was up 4.2 cents or 466.7 percent to 5.1 cents with 454.6 million shares traded.

## MESOBLAST

Mesoblast has requested a trading halt “pending an announcement ... in relation to a proposed financing”.

Biotech Daily received a copy of a Bell Potter ‘deal sheet’ which said that Mesoblast was expecting to raise \$75 million at \$2.00 a share – a 3.1 percent discount to the 10-day volume-weighted average price.

The Bell Potter deal sheet said that Mesoblast expected to use \$40 million to prepare for the potential commercial launch of Remestemcel-L for the treatment of steroid refractory acute graft-versus-host disease, including product inventory and a targeted biologics sales force, \$25 million for its back pain and heart failure phase III programs and \$10 million to working capital and general corporate purposes.

Trading will resume on October 3, 2019 or on an earlier announcement.

Mesoblast last traded at \$2.14.

## BENITEC BIOPHARMA

Benitec says it will raise \$US2.25 million (\$A3.33 million) in a placement of American depository shares at 70 US cents (\$A1.04) each.

Benitec said that sophisticated and professional US investors would be issued 2,800,000 American depository shares (ADS), equivalent to 56,000,000 shares at 5.2 cents each.

The company said that investors would be issued warrants to purchase up to 412,863 ADSs at 70 US cents, with a total of 8,256,260 warrants available.

Benitec said the pre-funded warrants may be exercised at any time from issue and did not expire, but investors were limited to 9.99 percent of the total number of ADSs on offer.

The company said that in a concurrent private placement, it would issue further purchase warrants to investors to additionally buy up to 3,212,864 ADSs, subject to shareholder approval.

Benitec said the purchase warrants would be issued at no cost with an exercise price of 70 US cents per ADS, expiring in five years after the issue.

The company said it would use the funds for product development and general corporate purposes.

Benitec fell 1.3 cents or 18.6 percent to 5.7 cents with 3.5 million shares traded.

## INNATE IMMUNOTHERAPEUTICS (NOW AMPLIA THERAPEUTICS)

Numerous media reports have referred to former Innate director and US Republican Congressman Chris Collins in relation to pending charges for insider trading.

Last year, Biotech Daily reported that US authorities had charged Mr Collins and relatives with insider trading in relation to Innate shares prior to the multiple sclerosis trial result announcement (BD: Jun 23, 27, 2017; Aug 9, 2018).

It appears all the media reports are copying a single US media report, which at the time of publication Biotech Daily was unable to confirm from official sources.

Biotech Daily has contacted the office of the Speaker of the US House of Representatives, Nancy Pelosi, as well as the US Department of Justice, regarding the case and is awaiting formal confirmation.

Last year, Innate acquired Amplia in a ‘backdoor listing’ for cancer therapeutics with Mr Collins resigning as a director on May 4 (BD: Mar 28, Apr 6, 2018).

Biotech Daily editor David Langsam owns Amplia shares.

Amplia was up one cent or 12.5 percent to nine cents.

## OPTHEA

Opthea says it has received \$14,636,973 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Acrux said the rebate related to research and development expenditure for the year to June 30, 2019.

Opthea was up 23 cents or 6.9 percent to \$3.58 with 298,268 shares traded.

## PARADIGM BIOPHARMACEUTICALS

Paradigm says its pentosan polysulfate sodium for knee osteoarthritis pain reduces pain by inhibiting nerve growth factor production in bone cells.

Paradigm said that nerve growth factor was a mediator of pain which was produced by bone cells, or osteocytes, causing pain.

The company said pentosan polysulfate sodium could reduce the production of nerve growth factor by bone cells at the messenger ribonucleic acid level, instead of blocking the nerve growth factor after it had been produced.

Paradigm said that the inhibition of nerve growth factor gene expression by pentosan polysulfate sodium was a new discovered mechanism of action

The company said the research, titled 'Human osteocyte expression of Nerve Growth Factor: the effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis' was conducted by Paradigm with the University of Adelaide, published by the US Public Library of Science One and was available at:

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222602>.

Last year, Paradigm said its 112-patient, phase IIb trial showed that injected pentosan polysulfate sodium (PPS) significantly reduced knee osteoarthritis pain compared to placebo ( $p = 0.031$ ) (BD: Dec 18, 2018).

In May, the company said that knee pain in 205 osteoarthritis patients with bone bruising treated with injectable pentosane polysulfate sodium was reduced by an average 51.3 percent (BD: May 28, 2019).

Today, Paradigm said that the research explained the mechanism by which PPS reduced pain from osteoarthritis.

The company said it had filed Australian provision patents relating to discovery, titled 'Treatment of pain with polysulfated polysaccharides'.

Paradigm was up eight cents or 2.8 percent to \$2.96 with 1.2 million shares traded.

## SUDA PHARMACEUTICALS

Suda says the Australian Therapeutic Goods Administration has refused its appeal to reconsider approval of its Artimist oral spray for paediatric malaria.

In 2017, Suda said the TGA had accepted its Artimist marketing application for review, with the application including data from its ART004 phase III pivotal trial in 150 paediatric patients, showing the superiority of Artimist in reducing parasite count compared to standard-of-care intravenous quinine. (BD: April 3, 2017).

In April, the company said the TGA had issued a preliminary notice of denial for Artimist and in July said it had "strong grounds for an appeal" (BD: July 18, 2019).

Today, Suda said it had received the notice of decision from a delegate of the Federal Minister for Health Greg Hunt which uphold the original decision.

The company said it was disappointed with the outcome and would consult with its advisors to determine whether any further actions were recommended.

Suda fell 0.1 cents or 22.2 percent to 0.35 cents with 24.2 million shares traded.

### PHYLOGICA (TRADING AS PYC THERAPEUTICS)

Phylogica says it has established Vision Pharma Pty Ltd in partnership with the Perth-based Lions Eye Institute to develop a treatment for retinitis pigmentosa.

Phylogica said it had appointed Prof Sue Fletcher as chief of research and development, who was known for her work in the design of anti-sense oligonucleotides for rare diseases.

The company said the Vision program combined its cell penetrating peptide (CPP) delivery technology with a proprietary drug cargo known as an anti-sense oligonucleotide and would select a lead candidate for clinical development to treat childhood blindness disease retinitis pigmentosa.

Phylogica said it had granted Vision a non-exclusive licence for the use of its delivery technology, but did not disclose the financial terms.

Phylogica was up 0.1 cents or 2.3 percent to 4.5 cents with 7.1 million shares traded.

### NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific says Emtin-B can penetrate the retina and optic nerve in rabbits with no side effects and is a potential disease-modifying therapy for glaucoma.

Neuroscientific said that Emtin-B was modeled on metallothionein and previous studies have shown that metallothionein was "a powerful promoter of axonal regeneration of the completely severed mature optic nerve in [rats]" and the rabbit study indicated that Emtin-B could be developed into a disease modifying eye drop formulation.

The company said that a pig study at Perth's Lions Eye Institute would assess whether Emtin-B could protect the optic nerve astrocytes and retinal ganglion cells from damage associated with elevated intraocular pressure, with data available by the end of the year.

Neuroscientific said that Emtin-B "could be the first available disease modifying treatment of glaucoma due to its capacity to promote optic nerve regeneration".

The company said that the potential for reversing the glaucoma-induced damage to the optic nerve was "being heralded as a major potential health breakthrough by ophthalmologists".

Neuroscientific chief executive officer Matthew Liddelow said that glaucoma was "a vision-threatening disease that requires lifelong treatment and patient compliance".

"Our company is on the cusp of developing a new innovative treatment that will have the potential to address concerns with patient compliance, to increase efficacy and to potentially preserve sight for glaucoma patients," Mr Liddelow said.

Neuroscientific rose one cent or 4.1 percent to 25.5 cents with 11.7 million shares traded.

### VISIONEERING

Visioneering says it has appointed the Nagoya, Japan-based Menicon Co to distribute its Naturalvue contact lenses in Europe.

Visioneering said that Menicon was Japan's largest contact lens company and it would sell the multi-focal lenses through wholly-owned subsidiary NKL Contactlenzen BV under Menicon's brand name as 'Menicon Bloom Day' for myopia progression control.

The company said the agreement did not prohibit it from marketing, selling, or distributing Naturalvue MF in Europe under its own or others' brand names.

Visioneering said expected to receive \$US475,000 related to an initial stocking order under the agreement by December 31, 2019, pending regulatory review and approvals.

The company said there was no minimum purchase amounts after the initial order.

Visioneering was up 0.2 cents or 2.9 percent to seven cents with 1.1 million shares traded.

## CELLMID

Cellmid says Douglas GmbH will distribute its Évolis anti-aging hair care products in Germany, with Aeon International supplying China.

Cellmid said that its subsidiary, Advangen International, had a supply agreement with Dusseldorf, Germany-based beauty retailer Douglas GmbH to distribute its products on its on-line, German language platforms.

The company said the first six months of the deal would be focused on online sales, beginning in early October.

Cellmid said it had begun negotiations for further European distribution opportunities with retailers in the UK, Germany, the Baltic states, and Eastern Europe.

The company said that through Advangen it had a 12-month, exclusive distribution deal with Aeon International, an Australian subsidiary of Chinese e-commerce company Habesul.

Cellmid said the deal with Aeon would distribute Evolis products in China through online e-commerce business including Alibaba, T-mall, JD.com, Kaola.com, Yunji, and Xiaohongshu.

Cellmid was unchanged at 23.5 cents.

## CRYOSITE

Cryosite says shareholders will vote to approve 1,300,000 options issued to executive chairman Bryan Dulhunty, exercisable at a 135 percent premium of six cents each.

In June, Cryosite said it had appointed non-executive chairman Bryan Dulhunty as executive chairman, and he would receive the 1.3 options based on a return to profitability and positive cash flow within two years (BD: June 27, 2019).

Today, the company said the options would vest after two years, subject to service and performance conditions, and expire five years after the date of issue.

Cryosite said the annual general meeting would vote on the adoption of the remuneration report and the re-election of director Andrew Kroger.

The meeting will be held at 13A Ferndell St, South Granville, Western Sydney, on November 1, 2019 at 9am AEDT.

Cryosite was untraded at 4.4 cents.

## PHARMAUST

Pharmaust has requested a trading halt "pending an announcement of a capital raising".

Trading will resume on October 3, 2019 or on an earlier announcement.

Pharmaust last traded at 15 cents.

## RESAPP HEALTH

Resapp has requested a trading halt "pending the release of an announcement regarding regulatory approval."

Trading will resume on October 3, 2019 or on an earlier announcement.

Resapp was up 0.25 cents or one percent to 24.75 cents with 2.8 million shares traded, prior to the trading halt.



## RACE ONCOLOGY

Race says it has appointed director Dr Daniel Tillett as its chief scientific officer.

Race said that Dr Tillett would assume responsibility for the company's research and development strategy, including manufacturing, and would assist chief executive officer Peter Molloy with licencing discussions and with investor communications.

The company said the chief scientific officer role was part-time, on average representing 40 percent of a full-time commitment.

Race said that Dr Tillett agreed to receive no cash compensation, but subject to shareholder approval, would receive 2.5 million options exercisable at 19 cents each within three years.

Race was up half a cent or four percent to 13 cents.

## BIOTRON

Biotron says it has establishment a scientific advisory board for its phase II HIV-1 clinical development program.

Biotron said the board would be chaired by Chicago's Northwestern University Feinberg School of Medicine Prof Robert Murphy, with members including Prof Steven Deeks, Prof Peter Hunt, Prof Christine Katlama, Prof Anthony Kelleher, Prof Esteban Martinez and Prof Carlos del Rio.

Biotron was up 1.1 cents or 15.1 percent to 8.4 cents with 42.1 million shares traded.

## PATRY'S

Patry's says it has appointed scientific advisory board member Dr Pamela Klein as a non-executive director.

In 2016, Patry's said Dr Klein joined the company as an advisor (BD: Dec 13, 2016).

The company said Dr Klein had more than 20 years' experience in the oncology and biopharmaceutical industry and was currently director of Argenx and Spring Bank Pharmaceuticals, was the principal and founder of oncology and drug development consultancy firm PMK Bioresearch and was previously the chief medical officer of Intellikline.

Patry's said Dr Klein holds a Doctor of medicine from Loyola University Chicago.

The company said Dr Klein's remuneration package included 4,000,000 options exercisable at 3.5 cents each,

Patry's was up 0.1 cents or 4.8 percent to 2.2 cents with three million shares traded.

## ONCOSIL MEDICAL

Last night's edition referred to the resignation of Dr Ash Soman as Oncosil's chief marketing officer.

Dr Soman was the company's chief medical officer.

Oncosil said that "day-to-day management and medical monitoring of the ongoing clinical trial program has been fully outsourced to the clinical research organization already contracted to support this program".

The mistake was made by the former busy Monday sub-editor who had trouble understanding the array of acronyms used in business and medicine.

She has been seconded to TLA Today.

We apologize unreservedly to Oncosil and Dr Ash Soman.

Oncosil was unchanged at 6.5 cents.

## BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT SEPTEMBER 30, 2019

<b>Company \$Am</b>	<b>Oct-18</b>	<b>Sep-19</b>	<b>Oct-19</b>
Cochlear	11,574	12,325	12,032
CSL	91,094	106,710	106,061
Resmed	22,643	29,579	28,487
<b>BDI-20</b>			
Avita	141	852	1,105
Clinuvel	1,054	1,252	1,209
Compumedics	80	128	109
Cyclopharm	73	93	79
Cynata	131	163	165
Ellex	101	85	79
Genetic Signatures	76	109	108
Immutep	142	81	89
Medical Developments	274	314	331
Mesoblast	1,038	733	1,067
Nanosonics	1,076	1,911	1,895
Neuren	123	190	202
Opthea	121	837	838
Paradigm	114	308	555
Pharmaxis	122	73	75
Polynovo	395	1,388	1,415
Pro Medicus	1,291	3,840	2,893
Starpharma	587	409	427
Telix	165	345	398
Volpara	161	318	358
<b>Second 20</b>			
Actinogen	56	9	10
Alterity (Prana)	23	23	25
Amplia (Innate)	12	5	4
Antisense	7	21	33
Dimerix	17	16	15
Impedimed	172	68	91
Imugene	76	76	76
Kazia	20	24	35
LBT Innovations	22	24	25
Next Science	168	474	530
Oncosil	125	45	41
Optiscan	27	20	22
Orthocell	24	63	62
Osprey	76	21	20
Patrys	41	25	23
Prescient	17	17	21
Proteomics	19	22	26
Resonance	10	47	53
Universal Biosensors	42	38	35
Uscom	21	15	17

\* Biotech Daily editor, David Langsam, owns shares in Acrux, Amplia, Benitec, Mesoblast, Nanosonics, Neuren, Patrys, Polynovo, Prana, Telix, Volpara and non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in a range of other biotechnology companies: <http://www.australianethical.com.au/who-we-invest-in>. These holdings are liable to change.

**Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053**  
**email: [editor@biotechdaily.com.au](mailto:editor@biotechdaily.com.au); [www.biotechdaily.com.au](http://www.biotechdaily.com.au); twitter: @biotech\_daily**